Yver Antoine's Form 4/A amendment
AmendedCentessa Pharmaceuticals plc (CNTA) · filed Nov 23, 2022
- Accession no.
- 0001847903-22-000096
- Filed
- Nov 23, 2022
- Trade date
- Oct 3, 2022
- Filing delay
- 51 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Oct 4, 2022
This filing lists 1 non-derivative transaction. It carries over 1 transaction from the original filing that it did not restate. Open-market sales total $47.2K. It was filed 51 days after the trade.
This amendment restates part of 0001847903-22-000065 (filed Oct 4, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Yver AntoineCIK 0001861878 | Officer (EVP & Chairman of Development) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 3, 2022 | Ordinary Shares | SSaleDisposed | −9,500 | $3.91F4 | −$37,145 | 780,251 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001847903-22-000065 (filed Oct 4, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2022 | Ordinary Shares | SSaleDisposed | −2,468 | $4.07F3 | −$10,044.76 | 787,283 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.93 to $4.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2
The transaction on September 30, 2022 previously reported on the Form 4 filed on October 4, 2022 was canceled in its entirety before settlement by the broker without instruction from the Issuer or Reporting Person.
- F3
The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted shares. These sales were automatic and intended to qualify under Rule 10b5-1.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.8800 to $3.9250, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F5
The Form 4 filed on October 4, 2022 reported an aggregate of 12,524 shares sold on October 3, 2022, of which (i) the transaction for the sale of 3,024 shares was canceled in its entirety before settlement by the broker without instruction from the Issuer or Reporting Person and (ii) 9,500 shares were sold as previously reported on the Form 4. No additional sales are being reported herein.
- F6
This amendment shall also be deemed to correct the total beneficial ownership reported by the Reporting Person in the subsequently filed Form 4 on November 3, 2022.